The eGFR parameter model helps predict blood drug concentration of amisulpride in patients with schizophrenia

Abstract

Objective This study aimed to examine inter-patient variability in amisulpride levels, using a multiple regression model with a dataset acquired from Chinese patients with schizophrenia. Methods Plasma concentrations of amisulpride (153 data from 128 patients) were analyzed by four-covariate model and eGFR model and were validated using goodness-of-fit and external prediction ability analyses. The amisulpride levels were detected by 2D-LC-UV system. Results The eGFR model adequately characterized amisulpride levels with adjusted R² 0.457. The dose and eGFR values significantly affected concentrations, as follows: amisulpride concentration = 838.561–9.169*eGFR + 1.273*dose. To remain below the laboratory alert level, recommended dose should remain below 300 mg/d, 500 mg/d, and 700 mg/d for patients with eGFR of 60 ml/min/1.73 m², 90 ml/min/1.73 m², and 120 ml/min/1.73 m², respectively. Once and twice daily treatment regiments yielded comparable trough concentration values. Conclusion The eGFR model is simpler and more accurate in predicting the concentration of AMI, and provides an evaluation method for safe and individualized use of AMI.